OT - from memory, so don't flame me: Morgan Stanley re-instated INFN to their outperform list. Raymond James downgraded INTC to underperform, joining the party of analysts who hate the stock, see long term growing headwinds. Uhg. I've not changed my position, but I'm cogitating on it. AMDis everyone's darling. At least James, in a statement bearich on semis, placed Nvidia at outperform. I've been thinking about taking money out of ROBO - an ETF of supposedly AI companies, which has lost 5-10% while I've owned it, and re-deploying it into NVDA and ISRG (Intuitive Surgical), both of which have been big winners. I also bought some Abbott Labs (ABT) yesterday, on the news that a study showed thier mitral valve clip, which cures mitral valve prolalpse, among other things, was hailed by cardiologists as a huge, game-changing success. At $30k a pop, they ought to be selling a lot of those, with no competition  in sight. Their heart pump study didn't do as well as Abiogen's, but analysts that were already bullish on ABT raised their PTs. Speaking of which MOrgan Stanley's PT on INFN was $9.50.